Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社（本社：東京、以下「アムジェン」）と北海道恵庭市（市長：原田裕）、株式会社キャンサースキャン（本社：東京、代表取締役：福吉潤、以下「キャンサースキャン」）は、2022年12月に「骨粗鬆症疾患啓発の推進に係る連携・協力（疾患啓発コモンズ）」（以下、本事業）を締結しました。アムジェンの骨領域における産官連携事業協定は、大阪府大阪市、千葉県佐倉市、北海道小樽市に続いて、4例目となります。
骨粗鬆症に起因する骨折の多くは、骨の強度が低下し、わずかな外力によって骨折が引き起こされる脆弱性骨折です。一度、脆弱性骨折を起こした骨粗鬆症の患者さんは、1年以内に次の骨折を連鎖的に引き起こす二次骨折のリスクが極めて高くなります。すでに生じた骨折自体が次の骨折の危険因子のひとつとされており、最初の骨折から1年以内に次の骨折を起こした人は23％、5年以内では54％に上るというデータ1もあることから、骨粗鬆症の早期治療は二次骨折予防のための重要な根拠となっています。この度の三者協定は、一度骨折を経験しているにもかかわらず骨粗鬆症の治療が開始されていない方々、治療を開始したものの中断されている方々に向けて二次骨折のリスクの啓発や、二次骨折予防のための医療機関受診を促し、骨折による寝たきりやそれに伴う介護負担の軽減を目的とするものです。
北海道恵庭市の住民基本台帳によると、令和 5年1月1 日現在、65歳以上の人口は20,008人となっており、高齢化率は 28.5％となっています。高齢者数の将来推計値を算出すると、団塊世代が 75 歳以上となる令和 7（2025）年度には 30.4％となることが予測されます2。また、団塊ジュニア世代が 65 歳以上となる令和 22（2040）年度には、高齢化率が36.5％となることが予想され、これは恵庭市民の 3 人に１人が 65 歳以上の高齢者となることを示しています2。また高齢化の進展と共に要支援・要介護認定者数も増加し、令和 7（2025）年度には 3,473 人、認定率は 16.4％まで上昇することが予測されています2。
こうした経緯から、本事業の実施にあたって、恵庭市とキャンサースキャン、アムジェンの三者は、恵庭市の40～74歳の国民健康保険の被保険者と75歳以上の後期高齢医療制度の被保険者を対象に、疾患啓発、行政と医療の連携支援を行い、地域の高齢化に伴う課題のひとつである骨折のうち、特に二次骨折予防のための環境づくりの構築を目指します。骨粗鬆症の検査や治療が勧められる方の受診行動を促し、骨粗鬆症患者さんが適切な医療を受け、介護予防や健康寿命の延伸に繋げられるよう、取り組んで参ります。
恵庭市について
北海道恵庭市は、札幌市と新千歳空港のほぼ中間に位置し、恵まれた交通アクセスと穏やかな気候風土を持つまちで、早くから住宅地整備を進めると共に、公共下水道や大学・専門学校、工業団地などの都市基盤の整備が進められ着実に人口が増えてきています。支笏洞爺国立公園を後背地とした恵庭渓谷には、「白扇の滝」や「ラルマナイの滝」などが点在し、観光スポットとして、また、最近では市民主導による花のまちづくりが盛んで「ガーデニングのまち」として全国的に知られるようになりました。令和4年6月25日から7月24日までの１か月間は、恵庭市をメイン会場として「ガーデンフェスタ北海道2022」が開催され、延べ34万人が来場しました。
ウェブサイト：https://www.city.eniwa.hokkaido.jp/
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、現在約700人の従業員が、「To
serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については www.amgen.co.jp をご覧になるか、https://www.facebook.com/amgenjapan
をフォローしてください。
株式会社キャンサースキャンについて
キャンサースキャンは、「人と社会を健康に」というミッションの達成に向け、データサイエンスとマーケティング、行動経済学、公衆衛生の専門知識を掛け合わせ、特定健診の受診勧奨や生活習慣病の重症化予防を目的とした受領勧奨、がん検診の受診勧奨、予防医療にかんする新たな事業開発等、日本の予防医療の推進を支援する各種事業を展開しております。
累計700以上の市町村での各種保健事業の実施支援を通じて、コミュニケーションを変え、社会の仕組みを変えながら、健康になるための行動変容にフリクションがない世界を目指しています。
ウェブサイト：https://cancerscan.jp/
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking
statements, including any statements on the outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to
manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including
anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc.
acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement
activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19
pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks
and uncertainties, including those discussed below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as
of the date of this news release and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL 03-4563-8610
株式会社キャンサースキャン
北村早紀
TEL 03-6420-3390
Mail info@cancerscan.jp
References